Bode L, The functional biology of human milk oligosaccharides, Early Hum Dev; 2015, Nov;91(11):619-22
Simrén M. Manipulating the Gut Microbiome as a Treatment Strategy for Functional Gastrointestinal Disorders. Gastroenterology; 2018; Oct, 155(4):960-962.
Conlon MA and Bird AR. The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. Nutrients. 2015; Jan; 7(1): 17–44.
Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut; 2001; 48: 20–7.
Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol; 2008; 6:765–71.
Staudacher HM, Irving PM, Lomer MC, et al. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol; 2014; 11:256-266.
National Institute for Health and Care Excellence. Irritable bowel syndrome in adults: diagnosis and management. Clinical Guideline [CG61]. Published: February 2008. Last updated: April 2017. Click here for text.
Lenhart A, Ferch C, Shaw M, and Chey WD. Use of Dietary Management in Irritable Bowel Syndrome: Results of a Survey of over 1500 United States Gastroenterologists. J Neurogastroenterol Motil.; 2018; Jul 30;24(3):437-451
Elison, E., et al., Oral supplementation of healthy adults with 2'-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr, 2016: p. 1-13.
Puccio, G., et al., Effects of infant formula with human milk oligosaccharides on growth and morbidity: a randomized multicenter trial. Journal of Pediatric Gastroenterology and Nutrition, 2017. 64(4): p. 624.
Storm, HM, et al., 2′-Fucosyllactose Is Well Tolerated in a 100% Whey, Partially Hydrolyzed Infant Formula With Bifidobacterium lactis: A Randomized Controlled Trial, Global Pediatric Health, 2019, Volume 6: 1–10
Rajilic-Stojanovic M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol; 2015; 110:278–287.
Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology; 2017; 152:111–123 e8.
Jalanka-Tuovinen J, Salonen A, Nikkila J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One; 2011; 6:e23035
Vigsnaes et al., The 11th Vahouny Fiber Symposium, 2017, Washington, US
Duboc, H., et al., Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil, 2012. 24(6): p. 513-20, e246-7.
Dior, M., et al., Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol Motil, 2016. 28(9): p. 1330-40.
Postler TS, Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metab; 2017; 26:110–30.
Martin-Gallausiaux C, Larraufie P, Jarry A, Béguet-Crespel F, Marinelli L et al. Butyrate Produced by Commensal Bacteria Down-Regulates Indolamine 2,3-Dioxygenase 1 (IDO-1) Expression via a Dual Mechanism in Human Intestinal Epithelial Cells. Front Immunol; 2018; Dec 11;9:2838.
Farup, P.G., K. Rudi, and K. Hestad, Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol; 2016. 16(1): p. 51.
Brint, E.K., et al., Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol, 2011. 106(2): p. 329-36
Bennet, S.M., et al., Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome. Am J Gastroenterol, 2016. 111(8): p. 1165-76
Bennet, S.M.P., et al., Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. Neurogastroenterol Motil, 2018. 30(12): p. e13468